← Trials/Trial dossier/NCT01787916

LIDO

CompletedPhase 4Results posted

52 Week Trial of Liraglutide in Type 1 Diabetes

Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.

Lead sponsor

CHU de Quebec-Universite Laval

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01787916

Org study ID2013LIDO

Timeline

Milestones

Study first posted2013-02-11estimated

Last update posted2018-01-05actual

Results first posted2018-01-05actual

Study start2013-04 (month precision)

Primary completion2015-04actual (month precision)

Study completion2015-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•type 1 diabetes non smoker BMI superior or equal to 25 diabetes duration superior or equal to 5 years

Exclusion criteria

•diabetic complication HbA1c superior or equal to 8.5% cancer acute or chronic pancreatitis

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

2 endpoints

Secondary/registry result/low confidence

Assessment of Changes on Adipose Tissue

Time frame:Measure changes in the composite at 24 and 52 weeks from baseline

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Assessment of Changes on Adipose Tissue

Time frame:Measure changes in the composite at 24 and 52 weeks from baseline

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Primary/registry result

Assessment of Changes in Glycemic Control by HbA1c.

Time frame:Measure changes in HbA1c at 24 and 52 weeks from baseline

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), percentage of HbA1c	95% CI
Liraglutide	0.3	—
Placebo	0.2	—

Primary/protocol endpoint

Assessment of Changes in Glycemic Control by HbA1c.

Time frame:Measure changes in HbA1c at 24 and 52 weeks from baseline

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Diabetes, obesity & metabolism2018 Jan (month)PMID28722271doi:10.1111/dom.13063via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.